Ready to start planning your care? Call us at 800-525-2225 to make an appointment.





Make an Appointment Back

HOSPITAL RESEARCH TEAMS

Made & Back Treatment The Liang Deng Lab

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership


History

Equality, diversity & inclusion

Annual report

Give to MSK

The Liang Deng Lab 1/9



Liang Deng, MD, PhD


Our laboratory is focused on understanding how poxviruses are detected by the host innate immune sensing mechanisms and how poxviruses evade host antiviral responses. We are also interested in the development of poxvirus-based oncolytic and immunotherapy for cancers including melanoma.

View Lab Overview




Research Projects

The Liang Deng Lab 2/9




The Liang Deng Lab 3/9



<

Featured News



At Work: Physician-Scientist Liang Deng

Physician-scientist Liang Deng cares for patients with melanoma and other skin cancers, and also conducts innovative research on poxviruses.

The Liang Deng Lab 4/9



Imagination to Discovery

Three emerging investigators are tackling the mysteries of biology and cancer at Memorial Sloan Kettering.

Publications Highlights

Yang, N., Wang, Y., Dai, P., Li, T., Zierhut, C., Tan, A., Zhang, Z., Pan, H., Li, Z., Ordureau, A., Xiang, J.Z., Hendrickson, R.C., Funabiki H., Chen, Z., Deng, L. (2023) Vaccinia E5 is a major inhibitor of the DNA sensor cGAS. *Nat Commun*, 14(1):2898. doi: 10.1038/s41467-023-38514-5 (PMC10201048).

Yang, N., *, Wang, Y., *, Liu, S., Tariq, S.B., Luna, J. M., Mazo G., Tan, A., Zhang, T., Wang, J., Yan, W., Choi, J., Rossi, A., Xiang, J.Z., Rice, C. M., Merghoub, T., Wolchok, J. D., and Deng, L. (2023) OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. *Journal Experimental Medicine* 220(8):e20221166. Epub 2023 May 5. PMID: 37145142.

Gu, L., Lin, E., Liu, S., Yang, N., Kurtansky, N., Neumann, N., Stoll, J., Lezcano, C., Pulitzer, M., Noor, S., Markova, A., Rossi, A., Dickson, M., and Deng L. (2023) Efficacy of Immunotherapy with Combination of Cryotherapy and Topical Imiquimod for Treatment of Kaposi Sarcoma. *Journal of Medical Virology*, 95(1):e28396. PMID: 36504005.

Yang, N., Garcia, A., Meyer, Tuschl T., Merghoub, T., Wolchok, J.D., and L. Deng (2022) Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. *npj Vaccines* (2022) 7(1):120. PMID: 36261460. https://doi.org/10.1038/s41541-022-00542-5.

Yang, N., Luna J.M., Dai, P., Wang, Y., Rice, C.M., and L. Deng. (2022). Lung type II alveolar

The Liang Deng Lab 5/9


epithelial cells collaborate with CCR2⁺ inflammatory monocytes in host defense against poxvirus infection. *Nature Communications* 13(1):1671. PMID: 35351885. PMCID: PMC896475.

View All Publications

People



The Liang Deng Lab 6/9



Liang Deng Lab Head

Shanza Baeer-Tariq Research Technician

Yueqi Wang Research Technician

Bharath Salla Research Technician



Ning Yang
Senior Research Scientist

Lab Alumni +

Lab Affiliations +

Get in Touch

- ✓ dengl@mskcc.orgLab Head Email
- 646-888-6011
 Office Phone
- 646-888-2744
 Office Fax
- 212-639-7144
 Lab Phone

Disclosures

The Liang Deng Lab 7/9

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Liang Deng discloses the following relationships and financial interests:

Immunogenesis, Inc.

Intellectual Property Rights

Imvaq Therapeutics

Equity; Intellectual Property Rights; Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures

The Liang Deng Lab 8/9

Communication preferences

Cookie preferences

Legal disclaimer

Accessibility statement

Privacy policy

Price transparency

Public notices

© 2024 Memorial Sloan Kettering Cancer Center

The Liang Deng Lab 9/9